Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).

PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).